

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. WWELL60.001APC	APPLICATION NO. 10/069,382
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Kupper, et al.	
		FILING DATE February 19, 2002	GROUP Unknown 1636

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
MB	1.	WO 98/39426	9/11/98	PCT				

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	2.	Kern, C., et al. (1997) Coxsackievirus-verstärkter endosomolytischer Gentransfer in kontraktile Kardiomyozyten. <i>Verh. Dtsch. Ges. Path.</i> 81:811.
MB	3.	Kramer, B., et al. (1997) Chinese hamster ovary cells are non-permissive towards infection with coxsackievirus B3 despite functional virus-receptor interactions. <i>Virus Research</i> 48:149-156.
MB	4.	Zell, R., et al. (1997) Coxsackievirus B3 (CVB3) variants expressing cytokine genes as a tool to influence the local immunity <i>in vivo</i> . <i>Immunobiology of Stuttgart</i> 197:336

O:\DOCS\MXG\MXG-1313.DOC:vb 042302

EXAMINER	<i>Michael R. Kupper</i>	DATE CONSIDERED	9-29-04
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			



SHEET 1 OF 1

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. WWELL60.001APC	APPLICATION NO. 10/069,382
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Kupper, et al.	
		FILING DATE February 19, 2002	GROUP Unknown 1636

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
MB	1.	Barr, E., et al. (1994) Efficient catheter-mediated gene transfer into the heart using replication-defective adenovirus. Gene Therapy 1:51-58.
NB	2.	Nabel, E. G., et al. (1990) Site-Specific Gene Expression in Vivo by Direct Gene Transfer into the Arterial Wall. Science 249:1285-1288.
MB	3.	Nabel, E. G., et al. (1989) Recombinant Gene Expression in Vivo Within Endothelial Cells of the Arterial Wall. Science 244:1342-1344.
MB	4.	Felgner, P. L., et al. (1987) Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure. PNAS 84:7413-7417.
MB	5.	Kandolf, R., and Hofschneider, P. H. (1985) Molecular cloning of the genome of a cardiotropic Coxsackie B3 virus: Full-length reverse-transcribed recombinant cDNA generates infectious virus in mammalian cells. PNAS 82:4818-4822.
MB	6.	Klump, W. M., et al. (1990) Complete Nucleotide Sequence of Infectious Coxsackievirus B3 cDNA: Two Initial 5' Uridine Residues Are Regained during Plus-Strand RNA Synthesis. J. Virol. 64(4):1573-1583.
MB	7.	Porter, D. C., et al. (1995) Encapsulation of Poliovirus Replicons Encoding the Complete Human Immunodeficiency Virus Type 1 gag Gene by Using a Complementation System Which Provides the P1 Capsid Protein in trans. J. Virol. 69(3):1548-1555.
MB	8.	Porter, D. C., et al. (1996) Release of Virus-Like Particles from Cells Infected with Poliovirus Replicons Which Express Human Immunodeficiency Virus Type 1 Gag. J. Virol. 70(4):2643-2649.

O:\DOCS\MXG\MXG-1475.DOC:vb
073102

EXAMINER <i>Michael Bley</i>	DATE CONSIDERED 9-29-07
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	